ADA 2018: CV Benefits of SGLT-2 Inhibitors

June 28, 2018
Kenneth J. Bender, PharmD, MA
Kenneth J. Bender, PharmD, MA

Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.